The approval of this accelerated pathway not only demonstrates the FDA’s full recognition of the quality, safety, and efficacy of the Phase 1 clinical data of hNPC01 in China, but also will ...
antiviral effectiveness of the drug in patients. The overall clinical trial will enroll approximately 80 patients. “This is an important milestone towards filing of the clinical trial application and ...
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– KPL-387 Phase 1 single ascending dose data support profile for monthly dosing –– Presentation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results